Sanofi agreed to acquire biopharmaceutical company Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx for approximately $1.7 billion and will also retain an 8% equity stake in New Inhibrx. Sanofi said that it expects to finance the transaction with available cash resources.
LyondellBasell (LYB) has agreed to acquire a 35% stake in Saudi Arabia-based National Petrochemical Industrial Company (Natpet) from Alujain for approximately $500 million. Closing of the transaction is subject to regulatory and other customary closing conditions.
Italian specialty additives manufacturer Italmatch Chemicals agreed to purchase the majority of shares of Alcolina, a Brazilian chemicals company specialized in water treatment for bioethanol, sugar production and industrial applications. Financial details of the transaction were not disclosed.
Following its long-term goal of extracting itself from a challenging operating environment in the Niger Delta, Shell agreed to sell its Nigerian onshore subsidiary Shell Petroleum Development Company of Nigeria (SPDC) to Renaissance, a consortium of five companies comprising four exploration and production companies based in Nigeria and an international energy group, for $1.3 billion.
Global specialty chemicals group Altana has announced to acquire Silberline, a US company that specializes in developing and manufacturing aluminum effect pigments utilized in various applications, ranging from automotive coatings and printing inks to plastics, protective coatings, and packaged consumer goods.
GSK has agreed to acquire biotech Aiolos Bio for a $1 billion upfront payment and up to $400 million for the achievement of certain milestones. Founded just last year, Aiolos is a San Francisco, USA and London, UK-based biopharmaceutical company that develops treatments for respiratory diseases.
Johnson & Johnson has entered into a definitive agreement to acquire Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The all-cash merger transaction for a total equity value of approximately €1.8 billion ($2.0 billion), or €1.75 billion ($1.9 billion) net of estimated cash acquired.
US Merck & Co., known as MSD outside of North America, intends to buy cancer drug developer Harpoon Therapeutics for $23.00 per share in cash for an approximate equity value of $680 million.
Arcadium Lithium announced the completion of the all-stock merger of equals between Allkem and Livent. With roughly $1.9 billion of combined total revenue in 2022 and a global team of more than 2,600 employees, the new, combined company is one of the largest integrated producers of lithium chemicals.
Japan’s AGI Group, a producer of scientific precision glassware, has acquired flow chemistry company Chemtrix, based in Echt, the Netherlands. Chemtrix’s flow reactor portfolio delivers increased process safety, reduced operating costs and new chemical possibilities at scales ranging from milligrams in the lab through to tons for manufacturing.
US drug manufacturer Eli Lilly has completed its acquisition of radiopharmaceutical company Point Biopharma for approximately $1.4 billion.
AstraZeneca has agreed to acquire Gracell Biotechnologies, a Chinese developer of cell therapies for the treatment of cancer and autoimmune diseases, for up to $1.2 billion. Only on Dec. 12, 2023, AstraZeneca announced that it was planning to acquire Icosavax for $1.2 billion.
Bristol Myers Squibb will acquire RayzeBio for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
Barentz has acquired Radian in India, reinforcing its product portfolio with color cosmetic ingredients. The move anticipates substantial growth in the Asia Pacific region. Radian's CEO, Manoj Botadra, and the current team will continue to manage operations, ensuring a smooth transition.
Bristol Myers Squibb (BMS) and Karuna Therapeutics have entered into a definitive merger agreement under which the US drug maker has agreed to acquire the Boston-based biopharmaceutical company for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the BMS and Karuna Boards of Directors.
Swiss Biosynth, a supplier of raw materials to the life science industry, has acquired VIO Chemicals, a Zurich, Switzerland-based company with leading chemical R&D expertise and a global network of large-scale manufacturing partners. Financial details of the transaction have not been disclosed.
Dutch fertilizer and industrial chemicals group OCI Global has agreed to sell 100% of its equity interests in its US nitrogen fertilizer facility Iowa Fertilizer Company (IFCO), located in Wever, Iowa, to Koch Ag & Energy Solutions (KAES) for $3.6 billion.
Abu Dhabi National Oil Company (ADNOC) has agreed to acquire OCI Global's entire majority stake in fertilizer producer Fertiglobe for $3.62 billion. Fertiglobe is a joint venture established in October 2019 between the state-owned oil company of the United Arab Emirates (UAE) and the Dutch fertilizer and industrial chemicals group.
Samyang Holdings has acquired the management rights of the U.S.-based specialty chemical manufacturer Verdant Specialty Solutions from private equity firm OpenGate Capital. The total acquisition was approximately €230 million ($250 million).
AstraZeneca has entered into an agreement to acquire Icosavax, a US biopharmaceutical company based in Seattle in a deal worth up to $1.1 billion. The company focuses on the development of differentiated vaccines with high potential using an innovative virus-like protein (VLP) particle platform.
In a move to complement its neuroscience portfolio, US drugmaker AbbVie has agreed to acquire Cerevel Therapeutics, which has a pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.
In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California.
In a move to focus on its core businesses, Finnish chemicals company Kemira has signed an agreement to divest its oil and gas-related portfolio for €260 million to Sterling Specialty Chemicals, a US subsidiary of Artek Industries, a global industrial chemicals group based in India.
US fertilizer producer CF Industries has completed the acquisition of the ammonia production complex of Incitec Pivot Limited (IPL) in Waggaman, Louisiana, USA, for $1.675 billion.
On Dec. 1, 2023, French chemicals and materials company Arkema has finalized the acquisition of Glenwood Private Equity’s 54% – based on a €728 million enterprise value – stake in South Korean company PI Advanced Materials (PIAM). Arkema said in a statement that this acquisition acquisition – first announced last June – complements its portfolio of high-performance technologies for the high-growth markets of advanced electronics and electric mobility.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
Olefins and polyolefins producer Borealis has signed an agreement to acquire Integra Plastics, a Bulgarian advanced mechanical recycling company. Closing of the transaction, for which no financial details were disclosed, is subject to customary regulatory approvals.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides.
Merck & Co. (MSD) and Caraway Therapeutics announced that the companies have agreed Merck & Co., through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to €557 million ($610 million), including an undisclosed upfront payment and contingent milestone payments.
Sweden’s Hexpol has acquired the American thermoplastic elastomers (TPE) compounder Star Thermoplastic Alloys and Rubbers for $26.5 million from Thomas A. Dieschbourg, who founded the company in 1993 and will remain as its president.
Azelis has agreed to acquire 100% of the shares of Agspec Australia, a leading distributor of crop nutrition, crop protection and specialty agricultural products in Australia. Financial terms of the transaction, which is expected to close in the first quarter of 2024 and is subject to customary closing conditions, were not disclosed.
Noramco, a US producer of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. Financial details were not disclosed.
DKSH has signed an agreement to acquire 100% of Bio-Strategy, said to be the largest independent distributor of scientific instruments in Australia and New Zealand, with a focus primarily on life sciences, medical & healthcare and environment & agriculture.
Anglo-Swedish drugmaker AstraZeneca entered into a collaboration and investment agreement with Cellectis, a French clinical-stage biotechnology company, to accelerate the development of therapeutics across oncology, immunology and rare diseases.
Clariant today announced that it has agreed to acquire Lucas Meyer Cosmetics, a provider of high-value ingredients for the cosmetics and personal care industry, from International Flavors & Fragrances (IFF) for a total cash consideration of €765 million ($810 million).
